menu
    • menu

    Company profile for Vanda Pharmaceuticals

    NEW Drugs in Dev: 13
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the use of novel approaches to deliver these new medicines to patients. Our CEO, Mihael Polymeropoulos, MD, founded Vanda in 2003 in partnership with Care Capital LLC, ...
    Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the use of novel approaches to deliver these new medicines to patients. Our CEO, Mihael Polymeropoulos, MD, founded Vanda in 2003 in partnership with Care Capital LLC, a prominent biopharmaceuticals-focused investment firm, and Bio*One Capital, an investment arm of the Singapore government with a focus on new biomedical enterprises.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vanda PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2200 Pennsylvania Ave NW Suite 300E Washington, DC 20037
    Telephone
    Telephone
    202-734-3400
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vanda Slides After FDA Again Rejects Hetlioz For Jet Lag
    Vanda Slides After FDA Again Rejects Hetlioz For Jet Lag

    08 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-receipt-of-fda-decision-letter-on-hetlioz-supplemental-new-drug-application-for-jet-lag-disorder-302656392.html

    PR NEWSWIRE
    08 Jan 2026
    Share Share
    Vanda Pharma Announces FDA Approval of NEREUS for Motion Sickness
    Vanda Pharma Announces FDA Approval of NEREUS for Motion Sickness

    30 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-approval-of-nereus-tradipitant-for-the-prevention-of-vomiting-induced-by-motion-a-historic-scientific-milestone-in-the-prevention-of-motion-sickness-302650965.html

    PR NEWSWIRE
    30 Dec 2025
    Share Share
    Vanda Pharma Files BLA for Imsidolimab in GPP Psoriasis
    Vanda Pharma Files BLA for Imsidolimab in GPP Psoriasis

    15 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302641858.html

    PR NEWSWIRE
    15 Dec 2025
    Share Share
    Vanda Pharma Joins J.P. Morgan Healthcare Conference
    Vanda Pharma Joins J.P. Morgan Healthcare Conference

    11 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-in-the-jp-morgan-healthcare-conference-302639678.html

    PR NEWSWIRE
    11 Dec 2025
    Share Share
    FDA Lifts Partial Hold on Motion Sickness Drug
    FDA Lifts Partial Hold on Motion Sickness Drug

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-lifts-partial-clinical-hold-on-tradipitant-for-motion-sickness-302633583.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    Vanda Pharma Updates Tradipitant for Motion Sickness
    Vanda Pharma Updates Tradipitant for Motion Sickness

    28 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-provides-regulatory-update-on-tradipitant-for-motion-sickness-302627878.html

    PR NEWSWIRE
    28 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search